rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David Shook

Chief Medical Officer

Company insider

Files Form 4 as: Chief Medical Officer, Lyell Immunopharma; Chief Medical Officer, Nkarta.

Every Form 4 they filed

In numbers

Trades disclosed
24
Buys
0
Sells
8
Bought
$0
Sold
$121K
Companies
2
Companies where not an officer
0
First trade
13 Jan 2023
Last trade
10 Sep 2026
Last filed
10 Sep 2026

Companies traded

Where they are an officer
LYEL Lyell ImmunopharmaOfficer · Biotechnology · last 10 Sep 20260 buys · 2 sells
NKTX NkartaOfficer · Biotechnology · last 15 Jan 20250 buys · 6 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Sep 2026filed 10 Sep 2026LYEL Lyell ImmunopharmaBiotechnologySEC FORM 4 Sold$6,350500 at $12.70filing
10 Sep 2026filed 10 Sep 2026LYEL Lyell ImmunopharmaBiotechnologySEC FORM 4 Sold$6,350500 at $12.70filing
10 Jun 2026filed 11 Jun 2026LYEL Lyell ImmunopharmaBiotechnologySEC FORM 4 Sold$25K1,977 at $12.64filing
10 Jun 2026filed 11 Jun 2026LYEL Lyell ImmunopharmaBiotechnologySEC FORM 4 Sold$25K1,977 at $12.64filing
10 Feb 2026filed 11 Feb 2026LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
10 Feb 2026filed 11 Feb 2026LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
9 Jun 2025filed 11 Jun 2025LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—43,750 at $0.00filing
9 Jun 2025filed 11 Jun 2025LYEL Lyell ImmunopharmaBiotechnologySEC FORM 4 Code A—21,900 at $0.00filing
15 Jan 2025filed 17 Jan 2025NKTX NkartaBiotechnologySEC FORM 4 Sold$19K8,638 at $2.20filing
3 Jan 2025filed 7 Jan 2025NKTX Nkartaoption or derivative · BiotechnologySEC FORM 4 Code A—117,500 at $0.00filing
3 Jan 2025filed 7 Jan 2025NKTX NkartaBiotechnologySEC FORM 4 Code A—59,000 at $0.00filing
21 Aug 2024filed 23 Aug 2024NKTX NkartaBiotechnologySEC FORM 4 Code A$6,9091,352 at $5.11filing
15 Jul 2024filed 31 Jul 2024NKTX Nkartaoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
15 Jul 2024filed 31 Jul 2024NKTX NkartaBiotechnologySEC FORM 4 Code A—23,421 at $0.00filing
18 Jun 2024filed 20 Jun 2024NKTX NkartaBiotechnologySEC FORM 4 Sold$2,554456 at $5.60filing
16 Jan 2024filed 18 Jan 2024NKTX NkartaBiotechnologySEC FORM 4 Sold$31K3,552 at $8.74filing
4 Jan 2024filed 8 Jan 2024NKTX Nkartaoption or derivative · BiotechnologySEC FORM 4 Code A—112,500 at $0.00filing
4 Jan 2024filed 8 Jan 2024NKTX NkartaBiotechnologySEC FORM 4 Code A—56,000 at $0.00filing
21 Aug 2023filed 23 Aug 2023NKTX NkartaBiotechnologySEC FORM 4 Sold$2,4361,331 at $1.83filing
1 Jul 2023filed 5 Jul 2023NKTX Nkartaoption or derivative · BiotechnologySEC FORM 4 Code A—208,000 at $0.00filing

Sectors

Health Care8

Buys in green, sells in red, by the company’s sector.

Related people

Jarrad Mattieu AguirreChief Medical Officer · Chief Medical Officer at Lyell Immunopharma, filing Form 4 there in the last year
Gary K. LeeChief Scientific Officer · Chief Scientific Officer at Lyell Immunopharma, filing Form 4 there in the last year
Stephen J. HillChief Operating Officer · Chief Operating Officer at Lyell Immunopharma, filing Form 4 there in the last year
Lynn SeelyPresident and CEO · President and CEO at Lyell Immunopharma, filing Form 4 there in the last year
Veronica Sanchez BulisVP, Corporate Controller · VP, Corporate Controller at Lyell Immunopharma, filing Form 4 there in the last year